Praxis Precision Medicines is a biotechnology company developing experimental new medicine for patients and families impacted by mutations in the SCN2A gene. We are using an antisense oligonucleotide (ASO) to specifically target the SCN2A gene. In a second program, we are using a persistent sodium current blocker. We invite you to join us as we progress these exciting new potential treatments through clinical development.